Table 3.

Frequent treatment-emergent adverse events (≥2% in any treatment group) by preferred term

		Ruxolitinib (n=281)*	Placebo (n=143)
Number of patients with ≥1 adverse event†		173 (62%)	93 (65%)
	Headache	23 (8%)	11 (8%)
	Diarrhoea	21 (7%)	12 (8%)
	Alanine aminotransferase increased	17 (6%)	6 (4%)
	COVID-19‡	12 (4%)	3 (2%)
	Cough	12 (4%)	3 (2%)
	Fatigue	10 (4%)	2 (1%)
	Constipation	9 (3%)	7 (5%)
	Hypokalaemia	8 (3%)	7 (5%)
	Transaminases increased	7 (2%)	3 (2%)
	Anxiety	6 (2%)	1 (1%)
	Asthenia	6 (2%)	0 (0%)
	Hyperkalaemia	6 (2%)	6 (4%)
	Nausea	6 (2%)	11 (8%)
	Neutropenia	6 (2%)	4 (3%)
	Pyrexia	6 (2%)	2 (1%)
	Thrombocytosis	6 (2%)	3 (2%)
	Aspartate aminotransferase increased	5 (2%)	3 (2%)
	Hypoxia	5 (2%)	5 (3%)
	Abdominal pain	4 (1%)	4 (3%)
	Dyspnoea	4 (1%)	3 (2%)
	Hyperglycaemia	4 (1%)	5 (3%)
	Hypertension	4 (1%)	3 (2%)
	Hypoproteinaemia	4 (1%)	3 (2%)
	Leukocytosis	4 (1%)	4 (3%)
	Insomnia	3 (1%)	4 (3%)
	Urinary tract infection	3 (1%)	5 (3%)
	Dizziness	2 (1%)	4 (3%)
	Hyponatremia	1 (<1%)	3 (2%)

A patient with multiple adverse events within a preferred term is counted only once for that preferred term.

^*Preferred terms are presented in descending order of frequency in the RUX group.

^†A patient with multiple adverse events is counted only once.

^‡COVID-19 relates to adverse events of worsening disease.